- Home
- RRR vs IMVT Comparison
RRR vs IMVT Comparison
Compare RRR & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRR | IMVT |
|---|---|---|
| Founded | 1976 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 5.4B |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RRR | IMVT |
|---|---|---|
| Price | $59.05 | $25.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $66.46 | $30.78 |
| AVG Volume (30 Days) | 805.2K | ★ 995.4K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 23.32 | N/A |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $2,011,483,000.00 | N/A |
| Revenue This Year | $3.26 | N/A |
| Revenue Next Year | $4.43 | N/A |
| P/E Ratio | $18.68 | ★ N/A |
| Revenue Growth | ★ 3.74 | N/A |
| 52 Week Low | $35.09 | $12.72 |
| 52 Week High | $68.99 | $29.25 |
Technical Indicators
Market Signals| Indicator | RRR | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 42.20 | 42.29 |
| Support Level | $55.64 | $24.63 |
| Resistance Level | $61.64 | $27.71 |
| Average True Range (ATR) | 2.31 | 1.14 |
| MACD | -0.43 | -0.18 |
| Stochastic Oscillator | 36.58 | 14.49 |
Price Performance
Historical ComparisonAbout RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.